



*(use as many sheets as necessary)*

**COMPLETE IF KNOWN**

<b>Application Number</b>	10/526,178
<b>Filing Date</b>	February 28, 2005
<b>First Named Inventor</b>	Raman K. Bakshi et al.
<b>Group Art Unit</b>	
<b>Examiner Name</b>	

Sheet	2	of	3	Attorney Docket Number	21140YP
-------	---	----	---	------------------------	---------

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
VJB			WO 02/15909		Merck & Co., Inc.	02/28/2002
			WO 02/059095		Eli Lilly and Company	08/01/2002
			WO 02/059107		Eli Lilly and Company	08/01/2002
			WO 02/059108		Eli Lilly and Company	08/01/2002
			WO 02/059117		Eli Lilly and Company	08/01/2002
			WO 02/068388		Merck & Co., Inc.	09/06/2002
			WO 03/007949		Merck & Co., Inc.	01/30/2003
			WO 03/031410		Neurocrine Biosciences, Inc.	04/17/2003
			WO 01/58891		Vertex Pharmaceuticals Incorporated	08/16/2001
VJB			WO 99/09984		Merck & Co., Inc.	03/04/1999

**Examiner  
Signature**

Date Considered

6/24/07

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.**

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

## STATEMENT BY APPLICANT

**COMPLETE IF KNOWN**

Sheet TRADE 3

3

of

3

Examiner  
Initials\*Cite  
No.

VB	AA	Wessells et al., J. of Urology, Vol. 160(2), (1998), pp. 389-393, "Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction..."
	AB	Giraud et al., Brain Research, Vol. 809 (1998), pp. 302-306, "Feeding effects of hypothalamic injection of melanocortin 4 receptor ligands"
	AC	Chen et al., Cell, Vol. 91 (1997), pp. 789-798, "Exocrine gland dysfunction in MC5-R-deficient mice: ..."
	AD	Chaki et al., Exp. Opin. Ther. Patents (2001), Vol. 11(11), pp. 1677-1692, "Recent advances in feeding suppressing agents: Potential therapeutic strategy for the treatment of obesity"
	AE	Dorr et al., Life Sciences, Vol. 58 (1996), pp. 1777-1784, "Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study"
	AF	Kask et al., Biochem. & Biophys. Res. Comm., Vol. 245 (1998), pp. 90-93, "Selective antagonist for the melanocortin 4 receptor (HS014) increases food intake in free-feeding rats"
	AG	Huszar et al., Cell, Vol. 88 (1997), pp. 131-141, "Targeted disruption of the melanocortin-4 receptor results in obesity in mice"
	AH	Wikberg et al., Pharma., Vol. 42 (2000), pp. 393-420, "New aspects on the melanocortins and their receptors"
	AI	Wikberg et al., Exp. Op. Ther. Patents, Vol. 11 (2001), pp. 61-76, "Melanocortin receptors: New opportunities in drug discovery"
	AJ	Andersson, Exp. Op. Ther. Patents, Vol. 11 (2001), pp. 1583-1592, "Ligands to the melanocortin receptors"
	AK	Peptides: Frontiers of Peptide Science, Fifteenth American Peptide Symposium, June 14-19, 1997 (Nashville, TN)
	AL	Corcos et al., Society for Neuroscience, Vol. 23 (1997), Abstract 267.9, "HP 228 is a potent agonist of melanocortin receptor 4, and significantly attenuates obesity and diabetes in Zucker fatty rats"
VB	AM	Marsh, Nat. Genet., Vol. 21 (1999), pp. 119-122, "Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides"

**Examiner  
Signature**

Date Considered

6/24/07

**SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.**

Computer Generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

**STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**COMPLETE IF KNOWN**

<b>Application Number</b>	10/526.178
---------------------------	------------

<b>Filing Date</b>	February 28, 2005
--------------------	-------------------

<b>First Named Inventor</b>	<b>R.K. Bakshi et al.</b>
-----------------------------	---------------------------

Group Art Unit	1642
----------------	------

Examiner Name

Sheet 1 of 2

Attorney Docket Number 21140YP

[illegible][illegible]

**Examiner  
Signature**

Date Considered

6/24/11

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.**

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

### STATEMENT BY APPLICANT

**COMPLETE IF KNOWN**

Sheet

2

of

2

Attorney Docket Number 21140YP

Examiner  
Initials\*Cite  
No.

**Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.**

**Examiner  
Signature**

✓ Balasubraman

Date Considered

6/24/07

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.**

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005